• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Silexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    5/14/26 4:11:39 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLXN alert in real time by email
    false000202241600-0000000972NASDAQNASDAQ00020224162026-05-142026-05-140002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2026-05-142026-05-140002022416slxn:OrdinarySharesParValue00135PerShareMember2026-05-142026-05-14



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): May 14, 2026

    Silexion Therapeutics Corp
    (Exact name of registrant as specified in its charter)

    Cayman Islands
     
    001-42253
     
    N/A
    (State or other jurisdiction
     
    (Commission File Number)
     
    (I.R.S. Employer
    of incorporation)
     

     
    Identification No.)

     

    12 Abba Hillel Road

    Ramat-Gan, Israel

     
    5250606
    (Address of principal executive offices)
     
    (Zip Code)

    +972-3-756-4999
    (Registrant’s telephone number, including area code)

    N/A
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Ordinary Shares, par value $0.0135 per share
     
    SLXN
     
    The Nasdaq Stock Market LLC
    Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share
     
    SLXNW
     
    The Nasdaq Stock Market LLC


    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




    Item 7.01 Regulation FD Disclosure.

    On May 14, 2026, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer”. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Form 8-K”) and is incorporated herein by reference.
     
    The information in this Item 7.01 of Form 8-K, including the information in the press release furnished pursuant to this Item 7.01, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in this Item 7.01, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

    Item 9.01 Financial Statements and Exhibits
     
    (d) Exhibits
     

     
    99.1

    Press Release dated May 14, 2026
     

     
    104

    Cover Page Interactive Data File (formatted in Inline XBRL)
     


    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    SILEXION THERAPEUTICS CORP
     
     
    Date: May 14, 2026
    /s/ Ilan Hadar
     
    Name:
    Ilan Hadar
     
    Title:
    Chief Executive Officer
     

    Get the next $SLXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLXN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SLXN
    SEC Filings

    View All

    SEC Form PRE 14A filed by Silexion Therapeutics Corp

    PRE 14A - Silexion Therapeutics Corp (0002022416) (Filer)

    6/3/26 4:58:02 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics Corp

    SCHEDULE 13D/A - Silexion Therapeutics Corp (0002022416) (Subject)

    5/29/26 4:00:17 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Corp filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Silexion Therapeutics Corp (0002022416) (Filer)

    5/29/26 7:00:25 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Shirvan Mitchell

    4 - Silexion Therapeutics Corp (0002022416) (Issuer)

    3/30/26 5:29:47 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Noy Shlomo was granted 9,091 units of Ordinary Shares (SEC Form 4)

    4 - Silexion Therapeutics Corp (0002022416) (Issuer)

    2/25/26 4:23:33 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Alon Ruth was granted 9,091 units of Ordinary Shares, increasing direct ownership by 800% to 10,228 units (SEC Form 4)

    4 - Silexion Therapeutics Corp (0002022416) (Issuer)

    2/23/26 4:20:33 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Silexion Therapeutics Announces 1-for-10 Reverse Share Split

    Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-10 reverse share split of its ordinary shares. The reverse share split will become effective after market close on May 28, 2026, and the Company's ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on May 29, 2026, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every ten ordina

    5/26/26 8:30:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany through the EU Clinical Trials Information System Phase 2/3 clinical trial initiation remains on track for the second quarter of 2026 Grand Cayman, May 18, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today provided an update on recent business developments following the release of its financial results for the first quarter ended

    5/18/26 8:30:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

    Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,995,092 of the Company's ordinary shares originally issued in August 2025 and September 2025 having a reduced exercise price of $0.50 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-290074) and an effective res

    5/15/26 8:27:23 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Leadership Updates

    Live Leadership Updates

    View All

    Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

    Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

    12/10/24 8:30:00 AM ET
    $BLRX
    $SLXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SLXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    11/20/24 6:15:12 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    8/22/24 6:44:28 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Silexion Therapeutics Corp

    SC 13D - Silexion Therapeutics Corp (0002022416) (Subject)

    8/22/24 5:23:46 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SLXN
    Financials

    Live finance-specific insights

    View All

    Silexion Therapeutics Announces 1-for-10 Reverse Share Split

    Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-10 reverse share split of its ordinary shares. The reverse share split will become effective after market close on May 28, 2026, and the Company's ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on May 29, 2026, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every ten ordina

    5/26/26 8:30:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Announces 1-for-15 Reverse Share Split

    Grand Cayman, Cayman Islands, July 16, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-15 reverse share split of its ordinary shares. The reverse share split will become effective after market close on July 28, 2025, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at market open on July 29, 2025, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every

    7/16/25 8:44:00 AM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Silexion Therapeutics Announces 1-for-9 Reverse Share Split

    GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-9 reverse share split of its ordinary shares. The reverse share split will become effective after market close on November 27, 2024, and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Global Market at market open on November 29, 2024, under the existing ticker symbol "SLXN." A new CUSIP number will be assigned to the post-reverse split shares. As a result of the reverse share split, every nine ordinary shares of

    11/22/24 4:30:00 PM ET
    $SLXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care